Gallstone Ileus following Endoscopic Stone Extraction by Yoshiya Yamauchi, Noritaka Wakui, Yasutsugu Asai, Nobuhiro Dan, Yuki Takeda, Nobuo Ueki, Takahumi Otsuka, Nobuyuki Oba, Shuta Nisinakagawa, Tatsuya Kojima

“…An 85-year-old woman was an outpatient treated at Tokyo Rosai Hospital for cirrhosis caused by hepatitis B. She had previously been diagnosed as having common bile duct stones, for which she underwent endoscopic retrograde cholangiopancreatography (ERCP). …”
Get full text

The role of the interleukin family in liver fibrosis by Zixin Zhang, Zixin Zhang, Jiahui Wang, Hui Li, Qun Niu, Qun Niu, Yujing Tao, Yujing Tao, Xin Zhao, Xin Zhao, Zijian Zeng, Zijian Zeng, Haijian Dong, Haijian Dong

“…It is a critical step in the progression from chronic liver disease to cirrhosis and hepatocellular carcinoma. No chemical or biological drugs have been approved for the treatment of liver fibrosis. …”
Get full text

Livogrit mitigates ANIT-induced cholestasis-like symptoms in an in vivo model by curbing hepatic inflammation and regulating BAX, TGF-β, MMP-9 and α-SMA gene expression by Acharya Balkrishna, Ritu Paliwal, Surjeet Singh, Rani Singh, Vivek Gohel, Rishabh Dev, Kunal Bhattacharya, Sandeep Sinha, Anurag Varshney

“…Bile duct constriction disrupts bile acid flow causing cholestasis, hepatic necrosis, fibrosis, and cirrhosis. The study investigated hepatoprotective effectiveness of Ayurvedic prescription herbal medicine “Livogrit” commercially available in India, against α-naphtylisothiocyanate (ANIT)-induced cholestasis-like symptoms in male Sprague-Dawley rats. …”
Get full text

Current Treatment Regimens and Promising Molecular Therapies for Chronic Hepatobiliary Diseases by Marilena Durazzo, Arianna Ferro, Victor Manuel Navarro-Tableros, Andrea Gaido, Paolo Fornengo, Fiorella Altruda, Renato Romagnoli, Søren K. Moestrup, Pier Luigi Calvo, Sharmila Fagoonee

“…Chronic hepatobiliary damage progressively leads to fibrosis, which may evolve into cirrhosis and/or hepatocellular carcinoma. The fight against the increasing incidence of liver-related morbidity and mortality is challenged by a lack of clinically validated early-stage biomarkers and the limited availability of effective anti-fibrotic therapies. …”
Get full text

Acute-on-Chronic Liver Failure in Pregnant Patients with Chronic Hepatitis B: A Retrospective Observational Case Series Study by Shiwei Wang, Haofeng Xiong, Changling Luo, Hong Zhao, Ying Fan, Ting Zhang, Lili Wang, Qi Wang, Wen Xie

“…Acute-on-chronic liver failure (ACLF) is common in patients with end-stage liver disease and chronic hepatitis B (CHB) or hepatitis B virus- (HBV-) related cirrhosis. To date, no uniform definition and management strategy are available for ACLF. …”
Get full text

The clinical role of blood coagulation and platelet receptors gene allelic variants in development of cryoglobulinemic vasculitis at chronic hepatitis C by Yekaterina Ye. Starostina, M. V. Sokolova, L. M. Samokhodskaya, T. П. Rozina, T. N. Krasnova, Ye. B. Yarovaya, N. A. Mukhin

“…Original study included overall 200 patients with CHCs and liver cirrhosis in its outcome, who were divided into 3 groups: patients without cryoglobulinemia (CG, n=123), those with asymptomatic cryoglobulinemia (ACG, n=40) and with cryoglobulinemic vasculitis (CGV, n=37). …”
Get full text

Identification of a postoperative survival scoring index for adult liver transplantation by Shuai Wang, Xiaohong Lin, Yefu Li, Zhonghao Xie, Ming Zhang, Yicheng Liang, Chuchen Zhu, Yuqi Dong, Ping Zeng, Xiaoshun He, Weiqiang Ju, Maogen Chen

“…Our index also functioned well in predicting long-term mortality, and it was more effective for patients with hepatitis B cirrhosis or hepatocellular carcinoma (HCC).Conclusions We constructed a simplified and effective postoperative survival scoring index to predict short-term complications and survival in adult LT patients.…”
Get full text

Outcome of Pleural Empyema Treated With Video-Assisted Thoracoscopic Surgery in Patients With Severe Co-Morbidities: An Observational Study by Vu HA, Nguyen NV, Le TD, Nguyen ST, Viet Le A, The Vu A, Van Nguyen B, Van Nguyen B, Thanh Quan N, An NV, Duc Nghiem T

“…Some comorbidities contained chronic obstructive pulmonary disease (COPD) (25.0%), spontaneous esophageal perforation (16.7%), liver cancer, cirrhosis, esophageal cancer, end-stage renal failure – chronic dialysis (8.7%). …”
Get full text

Recurrent Thrombotic Events after Discontinuation of Vitamin K Antagonist Treatment for Splanchnic Vein Thrombosis: A Multicenter Retrospective Cohort Study by Nicoletta Riva, Walter Ageno, Daniela Poli, Sophie Testa, Serena Rupoli, Rita Santoro, Teresa Lerede, Antonietta Piana, Monica Carpenedo, Alberto Nicolini, Piera Maria Ferrini, Giuliana Martini, Catello Mangione, Laura Contino, Carlo Bonfanti, Paolo Gresele, Alberto Tosetto

“…The recurrence rate was highest in the first year after VKA discontinuation (8.2/100’pt-y) and in patients with permanent risk factors (10.2/100’pt-y). Liver cirrhosis significantly increased the risk of recurrence. …”
Get full text

Long-term results of antiviral therapy in patients with chronic hepatitis C with sustained virologic response by T. M. Ignatova, T. N. Lopatkina, V. P. Chulanov, Ye. V. Gaydasheva, S. N. Batskikh, G. V. Mikhaylovskaya, D. T. Abdurakhmanov, S. Yu. Karpov, Ye. N. Nikulkina, O. A. Chernova

“…Overall 208 patients with CHC, including 12 at the stage of liver cirrhosis (LC), who achieved SVO were investigated. …”
Get full text

Extracellular Vesicles from Amnion-Derived Mesenchymal Stem Cells Ameliorate Hepatic Inflammation and Fibrosis in Rats by Masatsugu Ohara, Shunsuke Ohnishi, Hidetaka Hosono, Koji Yamamoto, Kohei Yuyama, Hideki Nakamura, Qingjie Fu, Osamu Maehara, Goki Suda, Naoya Sakamoto

“…There are no approved drug treatments for liver fibrosis and nonalcoholic steatohepatitis (NASH), an advanced stage of fibrosis which has rapidly become a major cause of cirrhosis. Therefore, development of anti-inflammatory and antifibrotic therapies is desired. …”
Get full text

Evaluation of the Efficacy of Lusutrombopag for Chronic Liver Disease Based on Pre‐Treatment Platelet Counts: A Retrospective Multicenter Study by Takayoshi Suga, Satoru Kakizaki, Atsushi Naganuma, Takeshi Hatanaka, Satoshi Takakusagi, Daichi Takizawa, Hirotaka Arai, Takashi Ueno, Keisuke Iizuka, Toru Fukuchi, Shuichi Saito, Hiroki Tojima, Yuichi Yamazaki, Toshio Uraoka

“…Patients with viral‐related cirrhosis showed a significantly greater change in platelet count than the others (29 100 vs. 19 200/μL, p = 0.012). …”
Get full text

Clinical Usefulness of Bioavailable Vitamin D and Impact of GC Genotyping on the Determination of Bioavailable Vitamin D in a Korean Population by Hyun-Young Kim, Jin Hyun Kim, Myeong Hee Jung, In Ae Cho, Youngjin Kim, Min-Chul Cho

“…The purpose of this study was to determine the utility of bioavailable 25(OH)D in assessing vitamin D status when vitamin D-binding protein (VDBP) was significantly altered by pregnancy and liver cirrhosis (LC). The role of genotyping of GC, a gene encoding VDBP, in the determination of bioavailable 25(OH)D concentration in a Korean population was also evaluated. …”
Get full text

Gut Microbiota at the Crossroad of Hepatic Oxidative Stress and MASLD by Fabrizio Termite, Sebastiano Archilei, Francesca D’Ambrosio, Lucrezia Petrucci, Nicholas Viceconti, Roberta Iaccarino, Antonio Liguori, Antonio Gasbarrini, Luca Miele

“…This disorder can lead to a range of pathological outcomes, including metabolic dysfunction-associated steatohepatitis (MASH) and cirrhosis. Despite extensive research, the molecular mechanisms driving MASLD initiation and progression remain incompletely understood. …”
Get full text

Frekuensi HBsAg Positif pada Uji Saring Darah di Palang Merah Indonesia Cabang Padang Tahun 2012 by Nadia Ventiani, Susila Lastri, Dian Pratiwi

“…<br />Kata kunci: HBsAg, donor darah, transfusi darah<br /><br /><br />Abstract <br />Hepatitis B virus infection could progress into chronic hepatitis, liver cirrhosis, liver cancer and even death. One mode of transmission is via blood transfusion. …”
Get full text

48-Week Outcome after Cessation of Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Patient and the Associated Factors with Relapse by Wen-xiong Xu, Qian Zhang, Xiang Zhu, Chao-shuang Lin, You-ming Chen, Hong Deng, Yong-yu Mei, Zhi-xin Zhao, Dong-ying Xie, Zhi-liang Gao, Chan Xie, Liang Peng

“…None died or developed liver failure, cirrhosis, or HCC. The 62 patients could be divided into 4 categories according to the 48-week clinical development of relapse. …”
Get full text

Human Umbilical Cord-Derived Mesenchymal Stem Cell Therapy Ameliorates Nonalcoholic Fatty Liver Disease in Obese Type 2 Diabetic Mice by Bing Li, Yu Cheng, Songyan Yu, Li Zang, Yaqi Yin, Jiejie Liu, Lin Zhang, Yiming Mu

“…Human umbilical cord-derived mesenchymal stem cells (UC-MSCs) have shown therapeutic potential for diabetes and hepatic disorders such as liver cirrhosis and fulminant hepatic failure. The present study is aimed at investigating the effect of human UC-MSCs on a mouse model of NAFLD and T2DM, characterized by obesity-induced hyperglycaemia, dyslipidaemia, hepatic steatosis, and liver dysfunction. …”
Get full text

Clinical and microbiological analysis of risk factors for breakthrough bloodstream infection during Tigecycline Therapy by Sol Jin, So Yun Lim, Yun Woo Lee, Heungsup Sung, Mi-Na Kim, Seongman Bae, Jiwon Jung, Min Jae Kim, Sung-Han Kim, Sang-Oh Lee, Sang-Ho Choi, Yang Soo Kim, Eun Hee Song, Yong Pil Chong

“…In multivariable analysis, independent risk factors for breakthrough BSI during tigecycline therapy were liver cirrhosis (adjusted odds ratio [aOR], 3.09), indwelling catheter (aOR, 3.42), previous Candida colonization (aOR, 14.95), and previous multi-drug resistant bacteria colonization (aOR, 10.30). …”
Get full text

MicroRNA-122 protects against interferon-α-induced hepatic inflammatory response via the Janus kinase–signal transducer and activator of transcription pathway by Fanwei Liu, Bowen Liu, Shanshan Xu, Yinhua Ni, Xiaoli Liu

“…Significant overlap in the epidemiology and coinfection of chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) has been identified, which accelerates the development of severe liver cirrhosis and hepatocellular carcinoma worldwide. Interferon-α (IFN-α), a cytokine with antiviral properties, exerts profound physiological effects on innate immunity by regulating interferon-stimulated genes (ISGs) within cells. …”
Get full text

HBV and HBsAg strongly reshape the phenotype, function, and metabolism of DCs according to patients’ clinical stage by Lucile Dumolard, Theophile Gerster, Florent Chuffart, Thomas Decaens, Marie-Noelle Hilleret, Sylvie Larrat, Philippe Saas, Evelyne Jouvin-Marche, David Durantel, Patrice N. Marche, Zuzana Macek Jilkova, Caroline Aspord

“…Infected individuals who fail to control the viral infection develop chronic hepatitis B and are at risk of developing life-threatening liver diseases, such as cirrhosis or liver cancer. Dendritic cells (DCs) play important roles in the immune response against HBV but are functionally impaired in patients with chronic hepatitis B. …”
Get full text